PRESS: Overcoming Regulatory Hurdles – Celadon Pharmaceuticals’ Journey to GMP Registration for Medicinal Cannabis
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) granted Celadon Pharmaceuticals Plc the first good manufacturing practice (GMP) registration since legalisation in 2018 for high Δ9-tetrahydrocannabinol (THC) cannabis active pharmaceutical ingredient (API).
James Short, CEO, and Arthur Wakeley, Managing Director of Celadon, share their insights on achieving regulatory compliance for medicinal cannabis in an interview with the European Pharmaceutical Review.
Read More: https://www.europeanpharmaceuticalreview.com/article/179459/medicinal-cannabis-the-route-to-good-manufacturing-practice-registration/
OTHER POSTS
-
PRESS: Britain could be getting high on the benefits of a full-scale medical cannabis industry
-
PRESS: British Pain Society features Celadon Pharmaceuticals Plc
-
PRESS: Celadon Pharmaceutical’s CEO Jim Short featured discussing new MHRA framework
-
PRESS: Inside huge top-secret legal cannabis facility hidden away in Birmingham that is the size of three football pitches